---
title: "TEM: Q2 2026 delivered 22% revenue growth, net income turnaround, and major MRD expansion via acquisition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294408929.md"
description: "Q2 2026 saw 22% revenue growth to $382.5M, a swing to $5.6M net income, and strong gains in Diagnostics and Data & Applications. Guidance calls for 25% full-year revenue growth and positive cash flow by year-end, with the Personalis acquisition set to expand MRD capabilities.Original document: Tempus AI, Inc. [TEM] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T20:07:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294408929.md)
  - [en](https://longbridge.com/en/news/294408929.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294408929.md)
---

# TEM: Q2 2026 delivered 22% revenue growth, net income turnaround, and major MRD expansion via acquisition

Q2 2026 saw 22% revenue growth to $382.5M, a swing to $5.6M net income, and strong gains in Diagnostics and Data & Applications. Guidance calls for 25% full-year revenue growth and positive cash flow by year-end, with the Personalis acquisition set to expand MRD capabilities.

Original document: Tempus AI, Inc. \[TEM\] Slides Release — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [PSNL.US](https://longbridge.com/en/quote/PSNL.US.md)
- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md)

## Related News & Research

- [Tempus AI Q2 revenue slightly beats estimates](https://longbridge.com/en/news/294409431.md)
- [Personalis Q2 revenue rises 30%, beats estimates on expanded Medicare coverage](https://longbridge.com/en/news/294864658.md)
- [Tempus AI (NASDAQ:TEM) Director David Epstein Sells 370 Shares of Stock](https://longbridge.com/en/news/295018599.md)
- [Tempus AI CEO and Chairman Eric Lefkofsky disposes of USD 10.75 million in common shares](https://longbridge.com/en/news/294438460.md)
- [TEM: A $1.5B acquisition merges AI oncology and MRD tech to lead in cancer monitoring](https://longbridge.com/en/news/293215484.md)